in cases of: melanoma with varying clinical stages (0-IV) (n=62), dysplastic nevi (in which melanocytes are abnormal but not malignant (n=12)), and healthy donors (n=21) (Figure 1a and Supplementary Table S1 ). Compared to healthy donors, all cases of melanoma exhibited elevated blood CD14 + HLA-DR no/low cells (Figure 1b) , consistent with a prior report (Filipazzi et al., 2007) . Whereas blood CD14 + HLA-DR no/low cells in healthy donors had little-to-no expression of DC-HIL (0.1 ± 0.1% DC-HIL + cells among PBMCs), all cases of metastatic melanoma (stages III/IV) displayed high-level DC-HIL expression on these cells (2.9 ± 0.9% and 2.6 ± 0.6%, respectively; t test p=0.001 vs. healthy donors) (Figure 1c ). Intermediate levels of DC-HIL expression were seen in blood CD14 + HLA-DR no/low cells of melanoma confined to skin (stages 0/I-II). Dysplastic nevi showed lower expression than skin-restricted melanoma, but higher than for healthy donors (p=0.01). Thus blood levels of DC-HIL + CD14 + HLA-DR no/low cells correlated with cancer progression, particularly in advanced stages. Other myeloid cells thought to have suppressor function (CD14 + IL-4Rα + , CD14 neg CD11b + CD15 + , and CD14 neg IL-4Rα + CD15 + ) also expressed DC-HIL at a range of 30-75% (Supplementary Figure 1) .
To determine whether melanoma was the cause of the elevated blood levels, we followed a new cohort of 9 patients with stage 0 melanoma and assayed for % DC-HIL + CD14 + HLA-DR no/low cells in their PBMCs (Figure 1d ), at 0, 1, 3, and 6 months after excision of the melanoma. At the time of resection (0 month), all subjects except one (subject M83) exhibited higher levels than healthy controls (0.3 to 12.8%) (Supplementary Table S2 ). Across the 3-month follow-up, these elevated levels declined significantly in 8 patients (Wald test, p=0.045) to an average of 0.4 %, close to that of 6 normal controls (Supplementary Table S3 ). Interestingly, in the case of one patient (M71), the % DC-HIL + CD14 + HLA-DR no/low cells that declined a month post-resection climbed back to a high level at 3 months, which coincided with discovery of a new melanoma in situ (stage 0), and then fell back after resection of this second melanoma. We concluded that melanoma is responsible (directly or indirectly) for acquisition of DC-HIL expression by CD14 + HLA-DR no/low cells. Because our mouse studies showed IFN-γ and IL-1β to induce DC-HIL expression by CD11b + Gr1 + cells, we speculate similar mechanisms for human CD14 + HLA-DR no/low cells. Do CD14 + HLA-DR no/low cells from melanoma patients suppress T-cell function and is DC-HIL responsible for that function? CD14 + HLA-DR no/low cells isolated from melanoma patients (vs. healthy donors) were cocultured with autologous T-cells activated by anti-CD2/CD3/CD28 Ab (Figure 2a ). CD14 + HLA-DR no/low cells from melanoma patients inhibited IFN-γ production by autologous T-cells dose-dependently and almost completely, whereas corresponding cells from healthy donors were weakly immunosuppressive.
Treatment with anti-DC-HIL mAb (but not control IgG) restored the T-cell IFN-γ response dose-dependently (up to 80%) (Figure 2b) . Moreover, treatment of total (unfractionated) PBMCs from melanoma patients with anti-DC-HIL mAb (but not with control IgG) enhanced the IFN-γ response, and this enhancement correlated positively with melanoma staging (Figure 2c ), but negatively with IFN-γ levels from IgG-treated PBMCs (Figure 2d ).
Our outcomes indicated that neutralizing DC-HIL's T cell-suppressive function could be beneficial to melanoma patients. Among currently available treatments for melanoma, the most closely related to a DC-HIL antagonist are humanized mAb directed against CTLA-4 (ipilimumab) or PD-1 (lambrolizumab). Both treatments have been shown to prolong survival of patients with metastatic melanoma (Hamid et al., 2013; Hodi et al., 2010) , presumably by blocking the inhibitory functions of CTLA-4 and PD-1, respectively. However, their benefits have been limited by development of autoimmune disease causing dermatitis, hepatitis, colitis, and in many cases, death (Hodi et al., 2010) , making the search for even better treatments important.
Our mouse studies showed that, unlike DC-HIL, the ligands for CTLA-4 (CD80 and CD86) and for PD-1 (PD-L1) are not critically involved in the T-cell suppressor function of myeloid cells. Moreover, both CTLA-4 and PD-1 are expressed by most activated T-cells and regulate development of autoreactive T-cells via regulatory T-cell function (Gattinoni et al., 2006) . By contrast, SD-4 (the DC-HIL ligand) is expressed by only a restricted population of effector T-cells, with no impact on regulatory T-cell function (Chung et al., 2013) . Finally, CTLA-4 −/− or PD-1 −/− mice develop spontaneous autoimmune diseases (Nishimura et al., 1999; Tivol et al., 1995) causing early death, while DC-HIL −/− or syndecan-4 −/− mice survive without observable autoimmune diseases (unpublished data). These differences suggest strategies neutralizing DC-HIL function may restore T-cell function in melanoma patients via mechanisms different from CTLA-4 or PD-1 blockers.
In sum, the positive correlation between % blood DC-HIL + CD14 + HLA-DR no/low cells and advancing melanoma stage, this parameter's quick decline after resection of early melanoma, and the restoration by anti-DC-HIL mAb of the T-cell IFN-γ response in melanoma patients constitute strong bases for developing these cells as a useful biomarker and therapeutic target for melanoma. Our results should be confirmed by large, multi-centers studies.
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